<DOC>
	<DOCNO>NCT02570191</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability PEGASYS participants HBeAg-negative chronic HBV . The anticipated time study treatment 48 week , target sample size 60 individual .</brief_summary>
	<brief_title>A Study PEGASYS ( Peginterferon Alfa-2a 40KD ) Patients With Hepatitis B e Antigen ( HBeAg ) -Negative Chronic Hepatitis B Virus ( HBV )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult participant 1870 year age Positive test result HBsAg &gt; 6 month Naive treatment HBV On liver biopsy , liver disease consistent chronic HBV , without compensate cirrhosis Coinfection hepatitis A , C D , Human Immunodeficiency Virus ( HIV ) Decompensated liver disease Hepatocellular cancer Systemic antiviral , antineoplastic , immunomodulatory therapy less equal 6 month study drug Medical condition associate chronic liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>